和厚朴酚联合硼替佐米对骨髓瘤KM3细胞增殖和凋亡的作用

山东大学学报(医学版) ›› 2010, Vol. 48 ›› Issue (12): 32-36.

和厚朴酚联合硼替佐米对骨髓瘤KM3细胞增殖和凋亡的作用

李珊，李丽珍，宋强，赵川莉，闫树昕，王鲁群

山东大学齐鲁医院血液科，济南 250012

收稿日期:2010-07-02 发布日期:2010-12-16
通讯作者: 王鲁群（1964- ），男，教授，主要从事白血病、淋巴瘤及多发性骨髓瘤的研究。 E-mail:wanglq@sdu.edu.cn
作者简介:李珊（1985- ），女，硕士研究生，主要从事多发性骨髓瘤的研究。

Effects of honokiol and Bortezomib on proliferation and apoptosis in myeloma KM3 cells

LI Shan, LI Li-zhen, SONG Qiang, ZHAO Chuan-li, YAN Shu-xin, WANG Lu-qun

Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China

Received:2010-07-02 Published:2010-12-16

摘要/Abstract

摘要：

目的探讨和厚朴酚（HNK）及硼替佐米对人多发性骨髓瘤KM3细胞增殖的影响及诱导凋亡作用。方法本实验分实验组和对照组（A组），实验组分为HNK单药组（B、C、D、E、F、G组的药物质量浓度分别为4、6、8、10、12、15μg/mL）、硼替佐米单药组（H、I、J组的药物质量浓度分别为5、10、20ng/mL ）及二者联合用药组（K组为HNK 4μg/mL+硼替佐米5ng/mL， L组为HNK 4μg/mL+硼替佐米10ng/mL， M组为HNK 4μg/mL+硼替佐米20ng/mL ）。在不同的时间（24、48、72h）采用MTT比色法检测对照组和实验组细胞增殖活性; 采用流式细胞术检测对照组和实验组细胞凋亡的变化。结果和厚朴酚4～15μg/mL对KM3细胞作用24、48、72h的细胞增殖抑制率分别由20.38%升至80.54%、 27.45%升至89.99%、 44.94%升至90.91%，不同组、不同作用时间相比差异均有统计学意义（P<0. 05）。H组、I组、J组KM3细胞48h的细胞增殖抑制率分别是13.13%、36.22%、53.99%，各组间差异有统计学意义（P<0. 05）。K组、L组、M组作用48h的细胞增殖抑制率分别是52.68%、69.99%、78.53%，K组与H组、L组与I组、M组与J组比较差异有统计学意义（P<0. 05）。流式结果显示B组、C组、E组作用于KM3细胞24h和48h后细胞凋亡率分别是6.92%、16.15%、60.70%和18.84%、37.21%、86.07%，同一时间不同实验组之间差异有统计学意义（P<0. 05）。H组、I组作用于KM3细胞24、48h的细胞凋亡率分别是9.27%、17.87%和11.92%、53.51%，同一时间不同实验组之间差异有统计学意义（P<0.05）。K组、L组作用于KM3细胞24、48h，细胞凋亡率分别是15.75%、22.18%和35.96%、74.70%，K组、L组细胞凋亡率明显高于H组、I组，差异有统计学意义（P<0.05）。结论和厚朴酚与硼替佐米均可诱导KM3细胞凋亡，抑制KM3细胞的增殖，两者联合作用能显著提高KM3细胞的凋亡率，增强抑制KM3细胞的生长作用。

关键词: 和厚朴酚；硼替佐米；KM3细胞；生长抑制；凋亡

Abstract:

Objective To investigate the anti-proliferative and apoptosis effects induced by Honokiol (HNK) and bortezomib on KM3 human multiple myeloma cell line in vitro． Methods Samples were divided into control group and experimental group, and the latter was further subdivided into HNK treatment group (group B, C, D, E, F, G at respective concentrations of 4,6,8,10,12,15μg / mL), bortezomib treatment group (group H, I, J at respective concentration of 5,10,20μg / mL), and combined treatment group (group K,L, M with HNK 4μg/mL + bortezomib 5ng/mL, HNK4μg/mL + bortezomib 10ng / mL and HNK4μg/mL + bortezomib 20ng/mL, respectively). MTT colorimetric assay were performed to assess the cell proliferation, and cell apoptosis were determined by PI and Annexin V fluorescent staining on flow cytometry. Results Honokiol, at concentrations between 4-15ug/mL, showed significantinhibiting effect on KM3 cell proliferation. At 24h, 48h, and 72h, the inhibition rate rose from 20.38%, 27.45% and 44.94% to 80.54%, 89.99% and 90.91%, respectively. There were significant differences among different groups, or at different time points. The inhibition rates of honokiol on KM3 cells at 48h in H, I, J, K, L, M were 3.13%, 36.22%, 53.99%, 52.68%, 69.99%, 78.53%, respectively. There were considerable differences between K and H, L and I, or M and J (P<0. 05). Apoptosis rate of KM3 cells in B, C, E at 24h and 48h were 6.92%、16.15%、60.70% and 18.84%、37.21%、86.07%, respectively. There were significant differences in apoptosis among different groups at the same time point(P<0. 05). Apoptosis rate of KM3 cells in H and I group were 9.27% and 17.87% at 24h, 11.92% and 53.51% at 48h. Statistical differences were found in apoptosis between H and I group (P<0. 05). Apoptosis rates of KM3 cells in K and L group were 15.75% and 22.18% at 24h, 35.96% and 74.70% at 48h. The apoptosis rates in K and L group were significantly higher than H and I group (P<0. 05). Conclusion Honokiol and bortezomib can inhibit the proliferation of KM3 cells and induce cell apoptosis, moreover, the combination of honokiol and bortezomib can increase the apoptosis rates and enhance cytotoxic activity of KM3 cells.

Key words: Honokiol； bortezomib; KM3 cell line; Growth inhibition; Apoptosis

中图分类号:

R733.3

李珊，李丽珍，宋强，赵川莉，闫树昕，王鲁群. 和厚朴酚联合硼替佐米对骨髓瘤KM3细胞增殖和凋亡的作用[J]. 山东大学学报(医学版), 2010, 48(12): 32-36.

LI Shan, LI Li-zhen, SONG Qiang, ZHAO Chuan-li, YAN Shu-xin, WANG Lu-qun. Effects of honokiol and Bortezomib on proliferation and apoptosis in myeloma KM3 cells[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(12): 32-36.

参考文献

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

[1]	蒲业迪，李丽珍，马道新，董珂，赵川莉，宋强，王鲁群. 硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立[J]. 山东大学学报(医学版), 2013, 51(2): 33-.
[2]	李银柱1，徐文君2，崔景英2，任翠爱2 . 53例二磷酸盐相关颌骨坏死诊治的回顾性分析[J]. 山东大学学报(医学版), 2013, 51(1): 109-112.
[3]	张晶晶，马道新，孔海丽，王慧君，孙元欣，刘传方. 靶向AML1/ETO的siRNA增强Kasumi-1细胞对组蛋白去乙酰化酶抑制剂的敏感性[J]. 山东大学学报(医学版), 2011, 49(7): 68-73.
[4]	赵婷,宋强，李丽珍，王鲁群，赵川莉. 骨髓增生异常综合征患者EPO水平的测定及其受体的表达[J]. 山东大学学报(医学版), 2011, 49(1): 67-70.
[5]	卢菲, 刘传方，马道新，刘彦平，孔海丽，张晶晶. 5-氮-2′-脱氧胞苷对RPMI8226细胞增殖、凋亡及SOCS-1基因表达的影响[J]. 山东大学学报(医学版), 2010, 48(4): 45-.